Literature DB >> 21849661

Evaluating preclinical efficacy.

Mark A Atkinson1.   

Abstract

Recent disappointing results of clinical trials seeking type 1 diabetes (T1D) reversal suggest the need for a reevaluation of our translational efforts. This Commentary explores the need for standards in evaluating therapeutic efficacy in preclinical models of T1D.

Entities:  

Mesh：

Year:  2011        PMID： 21849661     DOI： 10.1126/scitranslmed.3002757

Source DB:  PubMed          Journal:  Sci Transl Med        ISSN： 1946-6234            Impact factor:   17.956


  17 in total

Review 1.  Comparative genetics: synergizing human and NOD mouse studies for identifying genetic causation of type 1 diabetes.

Authors:  John P Driver; Yi-Guang Chen; Clayton E Mathews
Journal:  Rev Diabet Stud       Date:  2012-12-28

Review 2.  The challenge of modulating β-cell autoimmunity in type 1 diabetes.

Authors:  Mark A Atkinson; Bart O Roep; Amanda Posgai; Daniel C S Wheeler; Mark Peakman
Journal:  Lancet Diabetes Endocrinol       Date:  2018-10-24       Impact factor: 32.069

Review 3.  Predictive validity in drug discovery: what it is, why it matters and how to improve it.

Authors:  Jack W Scannell; James Bosley; John A Hickman; Gerard R Dawson; Hubert Truebel; Guilherme S Ferreira; Duncan Richards; J Mark Treherne
Journal:  Nat Rev Drug Discov       Date:  2022-10-04       Impact factor: 112.288

Review 4.  Knockout mouse models of insulin signaling: Relevance past and future.

Authors:  Anne E Bunner; P Charukeshi Chandrasekera; Neal D Barnard
Journal:  World J Diabetes       Date:  2014-04-15

Review 5.  Type 1 diabetes.

Authors:  Mark A Atkinson; George S Eisenbarth; Aaron W Michels
Journal:  Lancet       Date:  2013-07-26       Impact factor: 79.321

6.  Development of standardized insulin treatment protocols for spontaneous rodent models of type 1 diabetes.

Authors:  Christian W Grant; Shane K Duclos; Catherine M Moran-Paul; Barak Yahalom; Rebecca S Tirabassi; Guillermo Arreaza-Rubin; Lisa M Spain; Dennis L Guberski
Journal:  Comp Med       Date:  2012-10       Impact factor: 0.982

7.  NKG2D Signaling Within the Pancreatic Islets Reduces NOD Diabetes and Increases Protective Central Memory CD8+ T-Cell Numbers.

Authors:  Andrew P Trembath; Kelsey L Krausz; Neekun Sharma; Ivan C Gerling; Clayton E Mathews; Mary A Markiewicz
Journal:  Diabetes       Date:  2020-06-13       Impact factor: 9.461

8.  Addition of rapamycin to anti-CD3 antibody improves long-term glycaemia control in diabetic NOD mice.

Authors:  Shira Perl; Jordan Perlman; R P Weitzel; Oswald Phang; Matthew M Hsieh; John Tisdale
Journal:  PLoS One       Date:  2013-06-24       Impact factor: 3.240

9.  Immune Depletion in Combination with Allogeneic Islets Permanently Restores Tolerance to Self-Antigens in Diabetic NOD Mice.

Authors:  Nicola Gagliani; Tatiana Jofra; Amanda L Posgai; Mark A Atkinson; Manuela Battaglia
Journal:  PLoS One       Date:  2015-11-18       Impact factor: 3.240

10.  Prevention or early cure of type 1 diabetes by intranasal administration of gliadin in NOD mice.

Authors:  David P Funda; Petra Fundova; Axel Kornerup Hansen; Karsten Buschard
Journal:  PLoS One       Date:  2014-04-11       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.